PHARMACOLOGY UPDATE

Naldemedine Tablets (Symproic) C-II

April 30, 2017

Naldemedine is indicated for the treatment of opioid-induced constipation in adults with chronic noncancer pain.

Issue Date: April 30, 2017

Table of Contents

Financial Disclosure: Internal Medicine Alert’s Physician Editor Stephen Brunton, MD, is a retained consultant for Abbott Diabetes, Actavis, AstraZeneca, Becton Dickinson, Boehringer Ingelheim, Cempra, Janssen, Lilly, Merck, Novo Nordisk, Sanofi, and Teva; he serves on the speakers bureau of AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, Novo Nordisk, and Teva. Contributing Editor Louis Kuritzky, MD, is a retained consultant for and on the speakers bureau of, Allergan, Daiichi Sankyo, Lilly, and Lundbeck. Peer Reviewer Gerald Roberts, MD; Editor Jonathan Springston; and Executive Editor Leslie Coplin report no financial relationships relevant to this field of study.

Subscription Publication Books & Study Guides Group & Site Licenses State CME/CE Requirements